Summary
Eli Lilly and Company's 2016 10-K filing highlights a year of revenue growth, primarily driven by strong performance in the U.S. market, with a 14% increase. This growth was supported by key products like Trulicity, Taltz, and Jardiance, alongside the positive impact of acquiring commercialization rights for Erbitux in North America. However, the company faced significant headwinds from the loss of patent exclusivity for several products, including Cymbalta and Zyprexa in key markets, which led to substantial revenue declines for these specific drugs. The company continued its substantial investment in research and development, a core strategy for long-term competitiveness, with R&D expenses reaching $5.24 billion. Lilly also made strategic acquisitions, notably in its Elanco Animal Health division, to diversify its portfolio. A key focus for investors is the ongoing challenge of patent expirations and the company's ability to innovate and bring new products to market to offset these losses. The report also details ongoing patent litigation, product liability claims, and the impact of evolving healthcare regulations and payer pressures.
Financial Highlights
53 data points| Revenue | $21.22B |
| Cost of Revenue | $5.65B |
| Gross Profit | $15.57B |
| R&D Expenses | $5.31B |
| SG&A Expenses | $6.53B |
| Interest Expense | $185.20M |
| Net Income | $2.74B |
| EPS (Basic) | $2.59 |
| EPS (Diluted) | $2.58 |
| Shares Outstanding (Basic) | 1.06B |
| Shares Outstanding (Diluted) | 1.06B |
Key Highlights
- 1Total revenue increased by 6% to $21.22 billion in 2016, with U.S. revenue showing a strong 14% growth, largely driven by new product launches and the Erbitux rights acquisition.
- 2Significant R&D investment continued, with expenses totaling $5.24 billion, underscoring the company's commitment to innovation and pipeline development.
- 3Several key products experienced significant revenue declines due to patent expirations and generic competition, including Cymbalta (outside U.S.) and Zyprexa (Japan), highlighting a critical risk factor for investors.
- 4The company completed the acquisition of Novartis Animal Health's U.S. vaccine portfolio in January 2017 for approximately $885 million, strengthening its Elanco division.
- 5New molecular entities approved in 2016 included Taltz (psoriasis, psoriatic arthritis) and Lartruvo (soft tissue sarcoma), with several others in Phase III trials, indicating a pipeline with future growth potential.
- 6The company faces ongoing patent litigation for key products like Alimta and Effient, with potential for material adverse effects on future results if unfavorable outcomes occur.
- 7Pressures on pharmaceutical pricing and reimbursement from both public and private payers in the U.S. and internationally are expected to continue, potentially impacting future revenues.